Skip to main navigation
Logo
  • Careers
  • Contact
  • Home
  • Company
    • Founder's Story
    • Senior Management
    • Board of Directors
  • Products
    • Overview
    • SUFENTANIL
    • DSUVIA
    • DZUVEO
    • Zalviso US
    • Zalviso EU
  • Partnering
  • Investors
    • Overview
    • News & Events
    • Stock Information
    • SEC Filings
    • Corporate Governance
    • Shareholder Services
  • Media
    • Overview
    • Press Releases
    • Publications
  • Military
  • Careers
  • Contact

Investors

Contents

News Releases

Keyword search

3/10/2022
AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
3/3/2022
AcelRx to Host Fourth Quarter and Full Year 2021 Financial Results Call and Webcast on March 10, 2022
2/1/2022
AcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery Procedures
1/27/2022
AcelRx Pharmaceuticals Announces Publication of an Article Highlighting the Utility of the Sufentanil Sublingual Tablet in Pain Medicine Procedures
1/12/2022
AcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet in Joint Replacement Surgery
1/10/2022
AcelRx Pharmaceuticals Announces the Closing of its Acquisition of Lowell Therapeutics
  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2
  • Print Page
  • RSS Feeds
  • Overview
  • News & Events
    • News Releases
    • Upcoming Events
    • Past Events
  • Stock Information
  • SEC Filings
  • Corporate Governance
  • Shareholder Services
  

© 2022 AcelRx Pharmaceuticals, Inc. All Rights Reserved.

Privacy Policy | Terms of Use | CA state requirements
NP-US-NP-0002   05/21